Antitumor Activity and Immunomodulatory Effects of the Intraperitoneal Administration of Kanglaite in Vivo in Lewis Lung Carcinoma

Pei Pan,Yan Wu,Zhu-Ying Guo,Rong Wang,Yu-Jie Wang,Yong-Fang Yuan

DOI: https://doi.org/10.1016/j.jep.2012.07.025

IF: 5.195

2012-01-01

Journal of Ethnopharmacology

Abstract:Aims of the study: Kanglaite (KLT) is a useful antitumor drug with proven effects when combined with chemotherapy, radiotherapy or surgery. We hypothesize that KLT has antitumor activity and immunomodulatory effects in Lewis lung carcinoma.Materials and methods: C57BL/6 mice with Lewis lung carcinoma were divided into four groups: the control group (C), cisplatin group (1 mg/kg, DDP), low KLT group (6.25 ml/kg body weight [L] and high KLT group (12.5 ml/kg body weight [H]). T cell proliferation was determined by the mu assay. Nuclear factor-kappa B (NF-kappa B), inhibitor kappa B alpha (I kappa B alpha), I kappa B kinase (IRK) and epidermal growth factor receptor (EGFR) levels were measured by western blotting. An enzyme-linked immunosorbent assay was used to analyze the expression of interleukin-2 (IL-2).Results: Intraperitoneal KLT significantly inhibited the growth of Lewis lung carcinoma, and the spleen index was significantly higher in the L and H groups than in the C group. KLT stimulated T cell proliferation in a dose-dependent manner. Treatment with KLT at either 6.25 or 12.5 ml/kg decreased the level of NF-kappa B in the nucleus in a dose-dependent manner, and KLT markedly decreased the expression of I kappa B alpha, IKK and EGFR in the cytoplasm of tumor cells and overall. IL-2 was significantly increased in the supernatant of splenocytes in the H group.Conclusions: These results demonstrate that KLT has pronounced antitumor and immunostimulatory activities in C57BL/6 mice with Lewis lung carcinoma. These may affect the regulation of NF-kappa B/I kappa B expression, in addition to cytokines such as IL-2 and EGFR. Further work needs to investigate the relevant signaling pathway effects, but our findings suggest that KLT may be a promising antitumor drug for clinical use. (C) 2012 Elsevier Ireland Ltd. All rights reserved.